Using Platelet-enriched Autologous Plasma to Improve Transplantation of Cryopreserved Ovarian Tissue in Women with Premature Ovarian Failure or Irregular Menstrual Cycles

What this Trial Is About

Researchers are evaluating the effects of injecting a patients own platelet-enriched plasma into the ovary during the transplantation of cryopreserved ovarian tissue. This study focuses on improving outcomes for women with conditions such as premature ovarian failure, irregular menstrual cycles, ovary injury, infertility, or menopause-related ovarian failure. The research is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna and aims to assess safety and effectiveness over time. The treatment being studied involves reimplanting cryopreserved ovarian tissue combined with platelet-enriched autologous plasma. This procedure is designed to potentially enhance the quality and function of the transplanted tissue. Participants will receive this specialized transplantation intervention as part of the study. During the study, participants will be monitored for safety during the first year after transplantation and for effectiveness over a period of up to nine years. Researchers will evaluate various health outcomes related to the transplantation process, including any complications or benefits. The total duration of participation may extend up to nine years to fully assess long-term effects.

Improving the Quality of Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma